{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-041885","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.387497+00:00","generated_at":"2026-05-30T11:51:31.655602+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MangoRx Board initiates strategic alternatives review to maximize shareholder value","bullets":["Formalized $150K promissory note with CEO's entity Cohen Enterprises at 8% interest, due Jan 2, 2025.","Board formed strategy committee to explore mergers, acquisitions, divestitures, and business combinations.","Process is in parallel with current operations; no timeline or assurance of any transaction.","Company previously disclosed $50K loan from March 2024 and $100K loan from April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-041885","json":"https://secwatch.observer/filing/0001493152-24-041885.json","markdown":"https://secwatch.observer/filing/0001493152-24-041885.md","text":"https://secwatch.observer/filing/0001493152-24-041885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224041885/0001493152-24-041885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224041885/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:51:31.655602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}